Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update

AADI 10.30.2024

SERA-AI Powered Highlights
Full Press ReleaseSEC FilingsOur AADI Tweets

About Gravity Analytica

Recent News

  • 12.20.2024 - Aadi Bioscience, Inc. Investor Call
  • 12.19.2024 - Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing
  • 12.19.2024 - Baiteng Zhao, PhD

Recent Filings

  • 01.21.2025 - PREM14A Preliminary proxy statements relating to merger or acquisition
  • 12.31.2024 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
  • 12.30.2024 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material

LOS ANGELES,Oct. 30, 2024/PRNewswire/ --Aadi Bioscience, Inc.(NASDAQ: AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of theAadi Biosciencewebsite ataadibio.com.

About Aadi Bioscience

Aadi is a precision oncology company focused on the commercialization of FYARRO®for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website atwww.aadibio.comand connect with us on Twitter and LinkedIn.

Contact:IR@aadibio.com

(PRNewsfoto/Aadi Bioscience)

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-third-quarter-2024-results-and-corporate-update-302291958.html

SOURCEAadi Bioscience

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com